Firstly, it lays the foundations to improve colon cancer treatment through optimal lipid lowering treatment in association with adjuvant chemotherapy in a subgroup of patients with KRAS mutated metastatic recto-sigmoid cancer. This evidence concerns the gene KRAS and rectosigmoid carcinoma.